Source of support: Departmental sources Background: Febrile neutropenia (FN) is a life-threatening condition that requires urgent management in the emergency de-partment (ED). Recent progress in the treatment of neutropenic fever has underscored the importance of risk stratification. In this study, we aimed to determine independent factors for prediction of poor outcomes in pa-tients with FN. Material/Methods: We retrospectively evaluated 200 chemotherapy-induced febrile neutropenic patients who visited the ED. Upon arrival at the ED, clinical data, including sex, age, vital signs, underlying systemic diseases, laboratory test re-sults, estimated GFR, blood cultures, CRP, radiologic examinations, and Multinational Association of Supportive ...
PurposeCurrent guidelines recommend prophylactic use of granulocyte-colony stimulating factors (G-CS...
analysis of febrile neutropenia occurrence in patients with non-Hodgkin lymphoma: data from the INC-...
PurposeCurrent guidelines recommend prophylactic use of granulocyte-colony stimulating factors (G-CS...
Background/Aims. Febrile neutropenia is considered as one of the most important and potentially life...
Aims: This thesis explored and examined the clinical factors associated with the outcomes of chemoth...
Background: Febrile Neutropenia (FN) in cancer patients is associated with a high mortality rate, ye...
BACKGROUND: Among patients who develop fever and neutropenia after having received cancer chemothera...
Objective: Febrile neutropenia (FN) is a major toxic responseto chemotherapy requiring prompt medica...
Objective: This study aimed to identify the risk factors associated with mortality in febrile neutro...
Background: Febrile neutropenia (FN) is the commonest fatal acute complication of cancer treatment i...
Background: Febrile neutropenia (FN) is a common occurrence during chemotherapy. Granulocyte colony-...
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the ...
BACKGROUND: Febrile neutropenic cancer patients represent a heterogeneous population with a limited ...
Infections are the most frequent cause of morbidity and mortality in neutropenic cancer patients. We...
SUMMARY Febrile neutropenia is a serious adverse effect of chemotherapy. It can lead to complication...
PurposeCurrent guidelines recommend prophylactic use of granulocyte-colony stimulating factors (G-CS...
analysis of febrile neutropenia occurrence in patients with non-Hodgkin lymphoma: data from the INC-...
PurposeCurrent guidelines recommend prophylactic use of granulocyte-colony stimulating factors (G-CS...
Background/Aims. Febrile neutropenia is considered as one of the most important and potentially life...
Aims: This thesis explored and examined the clinical factors associated with the outcomes of chemoth...
Background: Febrile Neutropenia (FN) in cancer patients is associated with a high mortality rate, ye...
BACKGROUND: Among patients who develop fever and neutropenia after having received cancer chemothera...
Objective: Febrile neutropenia (FN) is a major toxic responseto chemotherapy requiring prompt medica...
Objective: This study aimed to identify the risk factors associated with mortality in febrile neutro...
Background: Febrile neutropenia (FN) is the commonest fatal acute complication of cancer treatment i...
Background: Febrile neutropenia (FN) is a common occurrence during chemotherapy. Granulocyte colony-...
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the ...
BACKGROUND: Febrile neutropenic cancer patients represent a heterogeneous population with a limited ...
Infections are the most frequent cause of morbidity and mortality in neutropenic cancer patients. We...
SUMMARY Febrile neutropenia is a serious adverse effect of chemotherapy. It can lead to complication...
PurposeCurrent guidelines recommend prophylactic use of granulocyte-colony stimulating factors (G-CS...
analysis of febrile neutropenia occurrence in patients with non-Hodgkin lymphoma: data from the INC-...
PurposeCurrent guidelines recommend prophylactic use of granulocyte-colony stimulating factors (G-CS...